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ABSTRACT
Purpose: To evaluate the efficacy and safety of bimatoprost plus timolol fixed combination (BTFC) in
patients with primary open angle glaucoma (POAG) previously treated with dorzolamide plus timolol
fixed combination (DTFC).
Materials and methods: Retrospective, medical records review study. Medical records of patients with
POAG previously treated with DTFC and then switched to BTFC for poor intraocular pressure (IOP)
control or ocular discomfort were included in the analysis. One baseline IOP diurnal curve, and one
diurnal curve under each treatment were required to be eligible for this study. The primary outcome was
to compare the mean diurnal IOP between DTFC and BTFC. Secondary outcomes were to compare the
IOP diurnal fluctuation, and the percentage of patients achieving a target IOP <14, <16, and <18 mmHg
between the two treatments.
Results: Medical records of 96 patients were analyzed (mean age 65.8 years ± 7.2, range 39–89 years). The
mean diurnal IOP was 23.7 ± 3.8 mmHg at baseline, 16.9 ± 3.4 mmHg with DTFC and 15.1 ± 2.9 mmHg
after therapy was switched to BTFC (p < 0.0001 each treatment vs baseline; p < 0.0001 DTFC vs BTFC). The
proportion of patients achieving a mean diurnal IOP <18, <16, and <14 mmHg was 76%, 35.4%, and
12.5% with DTFC and 81.2%, 68.8%, and 37.5% with BTFC (p = 0.20, p < 0.01, and p < 0.0001 between the
two treatments, respectively). IOP fluctuation did not differ significantly between the treatments.
Conclusion: BTFC can provide additional lowering in the mean diurnal IOP in patients previously treated
with DTFC with no significant differences in the safety and tolerability profile.
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Intraocular pressure (IOP) lowering therapy is, currently, the
only accepted, evidence-based approach for the treatment of
glaucoma. Large, controlled, multicenter randomized studies
have demonstrated that reducing IOP can prevent glaucoma
onset from ocular hypertension1 and glaucoma progression in
patients with a confirmed diagnosis of glaucoma.2–4 In normal
tension glaucoma, a randomized clinical trial concluded that an
IOP lowering approach can reduce the risk of disease
progression.5 According to the European Glaucoma Society
Guidelines,6 IOP lowering treatment with monotherapy should
be the first approach. Combination therapy is the second-line
treatment option when an additional IOP lowering agent is
needed for adequate IOP control. This is in preference to the
addition of a second medication to the first that carries the risk
of lower patient compliance with an increase in the complexity
of the dosage regimen. A fixed combination (FC) of two drugs
in a single product offers the advantage of a simplified dosage
regimen. It has been shown that adherence to the treatment as
well as patient quality of life are higher with once-daily FC
therapy compared to the use of unfixed combinations of dif-
ferent drugs. A reduced risk of washout of the first adminis-
tered medication and a decreased exposure to preservative are
other advantages of FC.7–9
Prostaglandin analogs plus timolol FC and carbonic anhy-
drase inhibitor plus timolol FC are among the most com-
monly prescribed FCs in patients with glaucoma, however
only one report is available comparing these two classes of
IOP lowering agents.10 The aim of this retrospective study is
to compare the efficacy of bimatoprost plus timolol fixed
combination (BTFC) and dorzolamide plus timolol fixed
combination (DTFC) in patients with primary open angle
glaucoma.
Materials and methods
A retrospective, single center chart review of patients referred
to Eye Clinic San Giuseppe Hospital (Milan, Italy) from
January 2011 to January 2014 was conducted. For this study
the electronic hospital database was screened for “primary
open angle glaucoma” and then patients switched to BTFC
from the previous treatment with DTFC were identified. The
study and data accumulation were carried out with approval
from the Institutional Ethics Committee (San Giuseppe
Hospital, MultiMedica) and adhered to the tenets of the
Declaration of Helsinki.
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Inclusion criteria were the charts of patients older than 18
years with a diagnosis of primary open-angle glaucoma
according to the European Glaucoma Society Guidelines
criteria;6 best-corrected visual acuity ≥20/100 (Snellen acuity)
in each eye; treatment with DTFC (Cosopt, Merck,
Whitehouse Station, NJ) twice-daily for at least 3 months,
and with BTFC (Ganfort, Allergan, Irvine, California) once
in the evening for at least 3 months after the switch from
DTFC.
Exclusion criteria were a diagnosis of ocular hypertension,
angle closure or secondary glaucoma; ocular surgery or laser
trabeculoplasty 3 months before or during the treatment
period; ocular disease affecting IOP (for example uveitis);
the use of topical ocular medication with effects on IOP and
patients with a history of refractive surgery.
Study design
Every patient referred to the Glaucoma Unit of the Eye Clinic
San Giuseppe Hospital (Milan, Italy) receives a complete
ophthalmic examination together with a diurnal IOP curve
(with IOP measured at 8.00, 11.00, 14.00, and 17.00). IOP
measurements are performed by trained physician with cali-
brated Goldmann applanation tonometers and adverse events
related to medications are recorded in the charts. For the
patient charts to be included in the review, the following
diurnal IOP curves had to be available for analysis: one curve
at baseline (before any treatment), one curve with DTFC, and
one curve with BTFC. Only one eye per patient (the eye with
the higher baseline IOP or the right eye in case of equal
baseline IOPs) was selected for analysis. The patients that
were included in the study had been switched from DTFC to
BTFC either for inadequate IOP control (as judged by the
physician) or for ocular discomfort. Because there was no
washout period, we only analyzed the BTFC IOP curves per-
formed more than 12 weeks after the switch from previous
treatment with DTFC in order to minimize the impact of the
previous therapy.
Mean diurnal IOP was calculated as the mean of the four
IOP diurnal measurements from the daily curve. The mean
value of 2 measurements at each time point (or the median of
3 readings if the first 2 differed by more than 2 mm Hg) was
used in the calculations. The IOP fluctuation was calculated as
the difference between the highest and the lowest IOP readings
within the diurnal curve for each patient.
Outcome
The primary outcome was to compare the mean diurnal IOP
obtained with DTFC with the mean diurnal IOP after switch to
BTFC.
The secondary outcomes were to compare the diurnal IOP
fluctuation and the proportion of patients achieving a mean
diurnal IOP of less than 18 mmHg, less than 16 mmHg and
less than 14 mmHg between the two treatments. Adverse
events and side effects related to treatment were evaluated as
previously described.11
Statistical analysis
The difference in the mean intraocular pressure (IOP) between
treatments was evaluated using the paired t-test. The null
hypothesis of equal variations of mean diurnal IOP among
strata was evaluated using analysis of variance.
To correct for multiple comparisons at individual time
points, a Bonferroni adjustment was used. The proportion of
patients with a mean diurnal IOP less than 18, 16, and
14 mmHg in each of the two treatment groups was compared
using Mc-Nemar’s test. All reported p-values are two-sided. A
p-value <0.05 was considered statistically significant. All ana-
lyses were performed using R (www.r-project.org).
The study had a 90% power to identify a 1.0 mm Hg
difference in the mean diurnal IOP values and at the
individual time points assuming a standard deviation of
2.5 mm Hg if at least 90 patients were enrolled (two tailed
paired t-test, a = 0.01).
Results
Baseline demographics and patient characteristics
Among the patients referred to Eye Clinic San Giuseppe
Hospital from January 2011 to January 2014, 96 Caucasian
patients met the inclusion criteria and were included in the
analysis. The mean age of the patients was 65.8 years (SD 7.2,
range 39–89 years). Baseline patient characteristics (referring
to patients before they were put on DTFC) have been reported
in Table 1.
Efficacy
The mean diurnal IOP from the daily curve was 23.7 ±
3.8 mmHg (baseline), 16.9 ± 3.4 mmHg (with DTFC), and
15.1 ± 2.9 mmHg after therapy was switched to BTFC
(Figure 1, Table 2).
Both medications reduced mean IOP significantly when
compared with untreated baseline (p < 0.0001). When the
two medications were compared directly, BTFC showed a
greater IOP lowering efficacy than DTFC (p < 0.0001).
Variations of mean diurnal IOP were similar by age, sex and
previous treatments.
Table 1. Baseline patient characteristics (n = 96).




CCT, µicron (mean ± SD) 549 ± 23.2






CAI-timolol FC 10 (10.4%)
Brimonidinetimolol FC 9 (9.4%)
Brimonidine 7 (7.3%)
CAI 4 (4.2%)
PGAs = prostaglandin analogs.
BB = beta blockers.
CAI = carbonic anidrase inhibitor.
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The percentage IOP reduction from baseline was 28.1%
for DTFC and 36% for BTFC (p < 0.0001).
The proportion of patients with a mean diurnal IOP of less
than 18 mmHg, 16 mmHg, and 14 mmHg was 76%, 35.4%,
and 12.5% with DTFC and 81.2%, 68.8%, and 37.5% with
BTFC respectively (p = 0.20, p < 0.01, p < 0.0001).
The mean diurnal IOP fluctuation was 4.7 ± 2.6 mmHg
(baseline), 3.3 ± 1.5 mmHg (with DTFC), and 3.0 ±
1.6 mmHg after therapy was switched to BTFC (p <
0.0001 from baseline and each treatment; p = 0.17 for
DTFC compared to BTFC).
Safety and tolerability
Medical records reported severe conjunctival hyperemia in
2% (DTFC) and in 4.1% (BTFC), mild conjunctival hyper-
emia in 8.3% (DTFC) and in 14.5% (BTFC), moderate
keratitis in 3.1% (DTFC) and 2% (BTFC), mild keratitis
in 6.2% (DTFC) and 3.1% (BTFC) of patients. No severe
adverse events related to the therapy were reported for
either of the treatments at any time point.
Discussion
In this study, we retrospectively compared the diurnal IOP
lowering efficacy of DTFC and BTFC. Patients treated with
DTFC with poor IOP control (as judged by their treating
physician) or complaining of ocular discomfort were switched
to BTFC. Although both medications are fixed combinations of
two drugs, BTFC offers the advantage of a once-daily therapy
compared to the twice-daily therapy of DTFC. The simplified
regimen of a once-daily treatment has been proven to impact
positively on patient adherence to therapy and on quality of
life.9 Both medications significantly reduced IOP from
untreated baseline levels. Analysis based on age, gender, and
previous treatments revealed that variations of mean IOP were
similar among strata.
The once-daily BTFC obtained a significantly lower mean
diurnal IOP, and a significantly higher proportion of patients
achieving an established target IOP when compared to DTFC.
The mean diurnal IOP difference between the two medica-
tions was 1.84 mmHg in this study. This is likely to be
clinically meaningful since a reduction of 1 mmHg has been
reported to decrease the risk of progression in glaucoma by
between 10% and 19%.2,4
The 28.63% IOP reduction for DTFC and 36.39% IOP
reduction for BTFC compared to baseline is in agreement
with the expected IOP lowering effect of these drugs as
reported by Cheng and associates in their meta-analysis that
found a 29.9% and 34.3% mean relative reduction from base-
line for DTFC and BTFC respectively.12 The fixed combination
of bimatoprost and timolol has been shown to have a similar
IOP lowering efficacy to the unfixed combination of its two
active ingredients13 and a significantly superior efficacy com-
pared with each of its active components.14 In exfoliative
glaucoma, BTFC demonstrated better IOP control than
bimatoprost15 and than latanoprost monotherapy over 24
hours.16
In head-to-head studies BTFC was found to have a greater
IOP lowering efficacy than latanoprost plus timolol FC17,18 and
travoprost plus timolol FC.19,20 However, a recent prospective
study compared the efficacy of BTFC with latanoprost plus
timolol FC in patients switched from latanoprost monotherapy
and this study showed no significant differences in mean IOP
between the two fixed combinations.21 In addition, Schnober
Figure 1. Mean intraocular pressure ± 95% CI at each individual time point and
for the diurnal intraocular pressure for baseline, DTFC, and BTFC treatment
groups.
Table 2. Comparison of diurnal IOP and diurnal IOP fluctuation at baseline, with DTFC and with BTFC (n = 96).














08:00 24.7 (23.7–25.7) 17.6 (16.8–18.4) 15.5 (14.8–16.2) 2.1 (1.5–2.8) <0.0001* 7.1 (6.3–8.0) <0.0001* 9.2 (8.3–10.1) <0.0001*
11:00 23.7 (22.9–24.6) 17.2 (16.5–17.9) 15.7 (15.0–16.3) 1.5 (0.9–2.2) <0.0001* 6.5 (5.8–7.3) <0.0001* 8.1 (7.2–8.9) <0.0001*
14:00 23.6 (22.8–24.4) 16.5 (15.7–17.2) 14.6 (13.9–15.2) 1.9 (1.3–2.5) <0.0001* 7.1 (6.4–7.9) <0.0001* 9.0 (8.3–9.8) <0.0001*
17:00 22.8 (22.0–23.6) 16.4 (15.7–17.1) 14.6 (13.9–15.2) 1.8 (1.1–2.6) <0.0001* 6.4 (5.5–7.2) <0.0001* 8.2 (7.5–9.0) <0.0001*




1.8 (1.3–2.4) <0.0001 6.8 (6.1–7.5) <0.0001 8.6 (8.0–9.3) <0.0001
Mean diurnal IOP fluctuation 4.7 (4.1–5.2) 3.3 (2.9–3.6) 3.0 (2.6–3.3) 0.3 (−0.1–0.7) 0.1718 1.4 (0.9–1.9) <0.0001 1.7 (1.2–2.2) <0.0001
*Bonferroni adjusted p-values.
# Percentage reduction from baseline.
DTFC = dorzolamide-timolol fixed combination.
BTFC = bimatoprost-timolol fixed combination.
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and co-authors showed an additional IOP lowering effect when
patients previously treated with BTFC were changed to travo-
prost plus timolol FC.22
Aptel and co-workers performed a meta-analysis of clinical
trials comparing the different prostaglandin plus timolol FCs and
they concluded that a greater IOP lowering efficacy was achieved
with BTFC compared with either travoprost or latanoprost plus
timolol FC.23
Few studies have compared prostaglandin plus timolol FC
with carbonic anhydrase inhibitor plus timolol FC.10,24,25 In the
study by Shin and associates,24 253 patients inadequately con-
trolled by monotherapy were randomized to latanoprost plus
timolol FC (LTFC) or DTFC. The study group consisted of
both Caucasian subjects (63.7%) and African-Americans
(32.7%). The authors found that the IOP lowering effect was
slightly but statistically significantly greater with LTFC than
with DTFC. In a Cyenkel and co-authors study,25 thirty-two
Caucasian patients were randomized to DTFC or LTFC.
Although the IOP was lower with the prostaglandin plus timo-
lol FC compared to DTFC (19.5 mmHg with DTFC, and
18.9 mmHg with LTFC) the difference was not statistically
significant. The study by Jothi and associates is the only
study to date comparing BTFC with DTFC.10 The authors
found a superior IOP lowering efficacy in Indian patients
randomized to BTFC compared to DTFC.
An important difference between the current paper and the
work by Jothi et al. is in the design of the study as the former is a
retrospective analysis whereas the latter was a randomized, pro-
spective study. However, the current study has a larger sample
size and the mean IOP was obtained in each patient by diurnal
IOP curves as opposed to the single IOPmeasurement performed
at each study visit in the study by Jothi et al. Despite these
differences, the mean IOPs reported by Jothi et al. with each
treatment (15.45 mmHg with BTFC and 17.25 mmHg with
DTFC) were similar to our findings. The percentage IOP reduc-
tion from baseline was superior in the Jothi et al. study (45.77%
with BTFC and 35.41% with DTFC) because the baseline IOPs
were higher than in the current study. This difference may be
partially explained by the “trial effect” as the Jothi et al. study was
a randomized, prospective study. In addition, in the Jothi et al.
study, patients were randomized into two groups according to
their economic status and this could have biased the study in
terms of patient adherence to therapy. Finally, our study popula-
tion consisted of only Caucasian subjects, whereas that of Jothi
and co-authors consisted of only Indian participants, therefore
racial differences in terms of drug response need to be considered.
The PRESSURE study,26 a study comparing the prostaglandin
efficacy in different racial groups, did not find any significant
difference in terms of treatment effect between the 3 considered
medications (latanoprost, travoprost and bimatoprost) or
between the 2 ethnic groups (White or Other), and no interac-
tion between race and drug was detected. However, the
PRESSURE study did not evaluate prostaglandin plus timolol
FC and DTFC, and the sample size was too small to conclusively
exclude racial differences in drug response.
In this study, we also investigated IOP fluctuation and we
found that both treatments significantly lowered IOP fluctua-
tion compared to baseline. IOP fluctuation was lower with
BTFC that with DTFC, but this difference was not found to be
statistically significant. Although it has been suggested that
IOP fluctuation may play a role in glaucoma progression,
studies exploring this topic have reported mixed findings. In
the Advanced Glaucoma Intervention Study3 and in the study
by Hong et al.,27IOP fluctuation was one of the predictive
factors for glaucoma worsening. The Early Manifest
Glaucoma Trial,2 however, failed to prove that IOP fluctua-
tion is an independent risk factor for glaucoma progression.
The retrospective nature of this study does not allow an
accurate evaluation of the safety of the respective drugs, however
adverse events recorded in the medical charts were reported and
analyzed. Conjunctival hyperemia is the most common drug-
related adverse event of prostaglandins. BTFC has been reported
to be associated with a lower incidence of conjunctival hyperemia
than an unfixed combination of bimatoprost and timolol13 or
bimatoprost alone.14,15 These findings have been corroborated by
two recent meta-analyses reporting that prostaglandin plus timo-
lol FCs lead to a significantly lower incidence of ocular hyperemia
than monotherapy with their respective prostaglandins.21,28
In our work, the overall proportion of patients with treat-
ment related adverse event was 19.6% and 23.7% with DTFC
and BTFC respectively.
In common with the paper by Maruyama et al. that compared
BTFC with latanoprost plus timolol FC,21 we noted a slightly
higher proportion of patients showing conjunctival hyperemia
with BTFC (18.6% vs 10.3%). A slightly higher proportion of
patients showed superficial keratitis with DTFC (9.3% vs 5.1%).
These results suggest a similar safety and tolerability profile of
the two FCs and are in agreement with the findings of Jothi et al.10
We recognize the limitations of this study. First, this study
carries the attendant limitations of any retrospective analysis.
Second, there was no washout period between treatments. To
account for that, we only analyzed the IOP curves performed
more than 12 weeks after the previous treatment was changed.
During this period the effect of the drugs was likely to be
completely washed out.29–32 Third, functional outcomes were
not analyzed (it was not the aim of this study). Studies with
functional end points and with a longer follow-up are warranted
to elucidate the role of this difference in mean diurnal IOP on
glaucoma progression. Finally, our study population was a rela-
tively homogeneous group of Caucasian patients with moderate
glaucoma switched fromDTFC to BTFC, so the interpretation of
our findings should be restricted to similar patients.
In conclusion, we found that DTFC and BTFC significantly
reduced IOP compared to baseline. BTFC showed a greater IOP
lowering efficacy compared to the previous treatment with DTFC
in patients with open angle glaucoma. Our work suggests that
patients with poorly controlled IOP with DTFC are likely to
achieve a better IOP control when switched to BTFC.
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